Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: Non-Hodgkin's lymphoma

Annals of Hematology

Volumn 81, Issue 8, 2002, Pages 448-453

  Zallio, F ^a   Cuttica, A ^a   Caracciolo, D ^a   Gavarotti, P ^a   Bergui, L ^a   Giaretta, F ^a   Bondesan, P ^a   Tassi, V ^b   Gallo, E ^a   Pileri, A ^a   Tarella, C ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b AO S Giovanni Battista di Torino   (Italy)

Author keywords

Intensified chemotherapy; Mobilization; Non Hodgkin's lymphoma; Old age; Peripheral blood progenitor cells

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CEFTRIAXONE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; LENOGASTRIM; MELPHALAN; MESNA; MITOXANTRONE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOTRANSPLANTATION; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GM; DRUG TOLERABILITY; FEASIBILITY STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKAPHERESIS; MORTALITY; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; STEM CELL MOBILIZATION;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HODGKIN DISEASE; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036935455     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0492-1     Document Type: Article

References (39)

1. Ansell SM (1993) A phase II trial of chemotherapy combination in elderly patients with aggressive lymphoma. Ann Oncol 4 [Suppl 2]:172
2. Armitage JO, Potter JF (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. Increased complications with advancing age. J Am Geriatr Soc 32:269-273
3. Basser RL, To LB, Collins JP, Begley CG, Keefe D, Cebon J, Bashford J, Durrant S, Szer J, Kotasek D, Juttner CA, Russel J, Maher DW, Olver I, Sheridan WP, Fox RM, Green MD (1999) Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells in women with high risk stage II or III breast cancer: five year follow up. J Clin Oncol 17:82-92
4. Bastion Y, Blay JY, Divine M, Brice M, Bordessoule J, Sebban C, Blanc M, Tilly H, Ledelin P, Deconinck E, Salles B, Dumontet C, Briere J, Coiffier B (1997) Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment and survival - a Groupe d'étude des lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 15:2945-2953
5. Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B (1995) Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262
6. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J (1994) Peripheral blood stem cells (PBPCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825-831
7. Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M, Resegotti L (1994) P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 5:895-900
8. Carlo Stella C, Cazzola M, De Fabriths P, De Vincentiis A, Gianni AM, Lanza F, Lauria F, Lemoli RM, Tarella C, Zanon P, Tura S (1995) CD34-positive cells: biology and clinical relevance. Haematologica 80:367-387
9. Coiffier B (1994) What treatment for elderly patients with aggressive lymphoma? Ann Oncol 5:873-875
10. Connors JM, O'Reilly SE (1997) Treatment considerations in the elderly patient with lymphoma. Hematol Oncol Clin North Am 11:949-961
11. Cortelazzo S, Rossi A, Viero P, Bellavita P, Marchioli R, Marfisi RM, Rambaldi A, Barbui T (1997) BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. Br J Haematol 99:379-385
12. Danova M, Perotti C, Mora O, Lucotti C, Torretta L, Comolli G, Riccardi A, Salvaneschi L, Ascari E (1998) Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer. Oncol Rep 5:427-429
13. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN, Wilson HE (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 4:295-305
14. Gianni AM (1994) Where do we stand with respect to the use of peripheral blood progenitor cells? Ann Oncol 5:781-784
15. Gianni AM, Bregni M, Siena S, Brambilla C, di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New Engl J Med 336:1290-1297
16. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G (1989) Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 2:580-585
17. Gomez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C (1998) Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16:2352-2358
18. Gratwohl A, Passweg J, Baldomero H, Hermans J (1999) Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Bone Marrow Transplant. Bone Marrow Tranplant 24:231-245
19. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787-3794
20. Haas R, Moos M, Mohle R, dohner H, Witt B, Goldshmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W (1996) High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 17:149-155
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481
22. Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, Torromeo C, Mandelli F (1993) P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:2362-2369
23. O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS (1993) In search of an optimal regimen for elderly patients with advanced-stage diffuse-large cell lymphoma. J Clin Oncol 11:2250-2257
24. Palumbo A, Pileri A, Triolo S, Omedé P, Bruno B, Ciravegna G, Galliano M, Frieri R, Boccadoro M (1997) Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant 19:23-29
25. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, Omedé P, Tarella C, Pileri A, Boccadoro M (1999) Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood 94:1248-1253
26. Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ, Deakin DP, Ryder D, Wilkinson PM, Crowther D (1996) Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 14:586-592
27. Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG (1995) Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hemopoietic progenitors in whole blood. J Clin Oncol 13:148-156
28. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357
29. Shea TC, Mason JR, Breslin M, Bissent E, Mullen M, Taetle R (1994) Reinfusion and serial measurements of carboplatin-mobilized. peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy. J Clin Oncol 12:1012-1020
30. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B (1995) Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530-2539
31. Tarella C, Zallio F, Caracciolo D, Cherasco C, Bondesan P, Gavarotti P, Corradini P, Tassi V, Pileri A (1999) Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulkying in indolent lymphoma patients. Stem Cells 17:55-61
32. Tarella C, Castellino C, Cherasco C, Bondesan P, Giaretta F, Corradini P, Caracciolo D, Gavarotti P, Pileri A (1997) Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. Br J Haematol 99:41-46
33. Tarella C, Gavarotti P, Caracciolo D, Corradini P, Cherasco C, Castellino C, Gallo E, Pileri A (1995) Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rate in poor risk lymphomas. Ann Oncol 6 [Suppl 4]:3-8
34. Tepler I, Cannistra SA, Frei E III, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M (1993) Use of peripheral blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 11:1583-1591
35. Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, Bron D, Rosti G, Somers R, Zagonel V, Noordijk EM (1998) CHOP is the standard regimen in patients 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16:27-34
36. To LB, Haylock DN, Simmons PJ, Juttner CA (1997) The biology and clinical uses of blood stem cells. Blood 89:2233-2258
37. Vitolo U, Cortelazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L (1997) Intensified and high-dose chemotherapy with granulocyte colony stimulating factor and autologous stem cell transplantation support as first line therapy in high risk large cell lymphoma. J Clin Oncol 15:491-498
38. Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S (1997) Randomized trial with or without granulocyte colony stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 89:3974-3979
39. Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S (1999) Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 94:33-38